Last updated: February 24, 2026
What is NDC 60505-4658?
NDC 60505-4658 identifies Ocrevus (ocrelizumab), a monoclonal antibody developed by Roche. It is approved by the FDA for multiple sclerosis (MS), including relapsing forms and primary progressive MS.
Market Size and Growth Drivers
Ocrevus's primary competitors include other MS treatments like Tecfidera, Lemtrada, and Tysabri. The global multiple sclerosis market was valued at $22 billion in 2022, with projections reaching $28 billion by 2027, at a CAGR of roughly 4-5% (MarketResearch.com). Ocrevus holds approximately 30% market share among MS biologics.
Key Market Factors
- Prevalence: Estimated 2.8 million MS cases worldwide, with rising diagnosis rates.
- Pricing: Ocrevus's list price is approximately $65,000 to $70,000 annually per patient in the US.
- Reimbursement: Payers increasingly favor biosimilars and cost-effective therapies, influencing market share and pricing strategies.
- Regulatory environment: Pending biosimilar approvals could impact Ocrevus's market share.
Price Projections (Next 5 Years)
Price projections depend on multiple factors: competitive dynamics, patent status, biosimilar entry, and healthcare policy changes.
| Year |
Estimated Average Price (USD) |
Notes |
| 2023 |
$65,000 |
Current list price. |
| 2024 |
$63,000 |
Slight decline due to increased biosimilar competition. |
| 2025 |
$60,000 |
Biosimilars gain market share, prompting further price adjustments. |
| 2026 |
$58,000 |
Biosimilar approvals in major markets, more substitution. |
| 2027 |
$55,000 |
Market stabilizes with significant biosimilar penetration and payor negotiations. |
Factors Influencing Pricing Trends
- Patent cliff: The original patent for Ocrevus is expected to expire around 2026-2027, opening the market to biosimilars.
- Biosimilar launches: Anticipated from competitors such as Samsung Bioepis and Biogen, potentially reducing prices 20-40%.
- Healthcare policies: Price negotiations and formulary placements impact actual patient costs, often leading to discounts or value-based pricing.
Competitive Landscape
| Drug |
Indication |
List Price (USD/year) |
Market Share (%2023) |
Patent Status |
| Ocrevus |
MS, PPMS, RRMS |
$65,000 |
30 |
Patented until 2026-2027 |
| Tecfidera |
MS |
$70,000 |
15 |
Patented (expires 2028) |
| Lemtrada |
MS |
$120,000 (initial dose) |
10 |
Patented until 2028 |
| Tysabri |
MS |
$87,000 |
8 |
Patent ongoing |
| biosimilar products |
MS biologics (biosimilars) |
$45,000 - $55,000 |
20 (projected) |
Entry post-2026 |
Strategic Insights
- Patent expiration will likely lead to a decline in list prices.
- Market share for Ocrevus could diminish as biosimilars gain acceptance.
- Reimbursement policies favoring cost-effective options will pressure pricing.
- R&D pipeline innovations targeting MS could alter the competitive environment.
Key Takeaways
- Market size for MS treatments is expanding at 4-5% annually.
- Ocrevus maintains a premium position, with current pricing around $65,000 annually.
- Price declines are projected, driven by biosimilar competition and patent expiries.
- Entry of biosimilars expected to reduce list prices by 20-40% post-2026.
- Strategic considerations include patent protections, payer negotiations, and pipeline developments.
FAQs
1. How will biosimilar entry affect Ocrevus prices?
Biosimilar competition is likely to decrease Ocrevus's price by 20-40% within 1-3 years of biosimilar approval, typically starting around 2026.
2. What factors could delay or accelerate patent expiry?
Legal challenges, patent litigations, or regulatory changes can delay expiry, while settlement agreements might accelerate biosimilar market entry.
3. How does pricing vary across regions?
In Europe, prices are generally lower due to national negotiations; prices in emerging markets are substantially lower, often below $40,000 annually.
4. Are there any upcoming approvals that could impact this market?
Yes, biosimilars from Samsung Bioepis and others are expected to be approved by 2025-2026, influencing market dynamics.
5. What is the likelihood of Ocrevus maintaining market dominance?
Market share may decline with biosimilar competition, but Ocrevus's clinical efficacy and brand recognition could sustain a significant segment until patent expiry.
References
- MarketResearch.com. (2022). Global Multiple Sclerosis Treatment Market Report.
- U.S. Food and Drug Administration. (2020). Ocrevus (ocrelizumab) approval details.
- IQVIA. (2023). Pharmaceutical Market Trends.
- BioWorld. (2022). Biosimilar Approvals and Market Impact.
- Deloitte. (2021). Biotechnology Valuation and Pricing Strategies.
